Full Press Release Details
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial.
IMMP
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Key Takeaway: Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Price reaction · baseline $1.93 (2025-01-17 close) · hit after-hours · clean, no other IMMP news in the window
day 0 close · peak
-1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)